After all, Joe Papa and the new management team have a completely different business model. Even if all the corruption has left the company, many investors may still shun the stock for its severely tarnished reputation regardless of who's in charge. I'm not sure if a name change will help attract investors back, but it certainly wouldn't hurt the company at this point. Another US$2 billion may be raised Valeant is reportedly speaking with German company Carl Zeiss Meditec AG regarding the sale of Bausch & Lomb's eye surgery assets. According to Bloomberg, the deal could rake in about US$2 billion for Valeant, which would be a small step in bringing the debt back to reasonable levels. The acquisition spree produced a whopping US$30 billion in debt, but every deal is a step closer to bringing Valeant back on track. Joe Papa appears to be taking his time with the sale of assets, and I think that's the right way to go about the situation.